Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ BLPH opened at $0.01 on Friday. The company has a fifty day moving average of $0.02 and a 200 day moving average of $0.03. The company has a market capitalization of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.02.

Bellerophon Therapeutics Announces Dividend

The company also recently disclosed a dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 20th were given a $0.019 dividend. The ex-dividend date of this dividend was Thursday, December 19th. This represents a dividend yield of 117.8%.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.